Abstract： Objective： To investigate the potential mechanisms of Jiedu Fuzheng Decoction in the treatment of lung cancer based on network pharmacology from the perspective of target genes. Methods： Active components and related targets of Jiedu Fuzheng Decoction were collected through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP）. Lung cancer-related targets were gathered from the GeneCards database. The intersection of non-small cell lung cancer （NSCLC）-related targets and Jiedu Fuzheng Decoction active component targets was used to create a Venn diagram，identifying potential targets of Jiedu Fuzheng Decoction against NSCLC. The STRING database and Cytoscape 3.10.2 were used to construct a protein-protein interaction （PPI） network. The DAVID 6.8 database was utilized for Gene Ontology （GO） and biological function enrichment analysis，as well as Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analysis， to explore the anti-lung cancer mechanisms of Jiedu Fuzheng Decoction. Finally，molecular docking experiments were conducted using AutoDock Tools software to validate the core components and key target genes. Results： Seven active components of Jiedu Fuzheng Decoction were identified， with 1 414 component targets and 5 247 lung cancer-related target genes collected. After removing duplicates， 45 active components and 181 common targets were obtained. Jiedu Fuzheng Decoction may intervene in lung cancer through core targets such as β-sitosterol，quercetin，and acacetin，participating in biological processes such as oxidative stress response， reactive oxygen species response， nutrient level response， and lipopolysaccharide response. It affects pathways including lipid and atherosclerosis pathways，PI3K-Akt，and chemical carcinogenesis-receptor activation signaling pathways. Conclusion：Jiedu Fuzheng Decoction intervenes in lung cancer through multiple targets and pathways，providing theoretical support for further research into its mechanisms in treating lung cancer.